Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 5, 2006, Pages 1471-1478

  Mornex, Françoise ^a   Girard, Nicolas ^a   Scoazec, Jean Yves ^b   Bossard, Nadine ^a   Ychou, Marc ^c   Smith, Denis ^d   Seitz, Jean François ^e   Valette, Pierre Jean ^b   Roy, Pascal ^a   Rouanet, Philippe ^c   Ducreux, Michel ^f   Partensky, Christian ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemoradiation; Chemotherapy; Neoadjuvant treatment; Pancreatic adenocarcinoma; Radiotherapy; Surgery

Indexed keywords

DRUG PRODUCTS; OPTIMIZATION; RADIOTHERAPY; SURGERY; TUMORS;

CHEMORADIATION; NEOADJUVANT TREATMENT; PANCREATIC ADENOCARCINOMA;

CHEMOTHERAPY;

CISPLATIN; FLUOROURACIL;

ABDOMINAL BLEEDING; ADULT; AGED; ANEMIA; ARTICLE; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; FISTULA; FRANCE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEUROPATHY; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; SKIN DISEASE; STOMACH PARESIS; STOMATITIS; SURGICAL MORTALITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33746702065     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.02.054     Document Type: Article

References (26)

1. Bramhall S.R., Allum W.H., Jones A.G., et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands. An epidemiological study. Br J Surg 82 (1985) 111-115
2. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (1997) 621-633
3. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy after curative resection of pancreatic cancer. Cancer 59 (1987) 2006-2010
4. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (1999) 776-782
5. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15 (1997) 928-937
6. Wayne J.D., Abdalla E.K., Wolff R.A., et al. Localized adenocarcinoma of the pancreas. The rationale for preoperative chemoradiation. Oncologist 7 (2002) 34-45
7. Pingpank J.F., Hoffman J.P., Ross E.A., et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5 (2001) 121-130
8. Greene F.L., Page D.L., Felming I.D., Fritz A.G., Balch C.M., Haller D.G., and Morrow M. AJCC cancer staging manual. 6th ed (2002), Springer-Verlag, New York 157-164
9. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
10. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0. Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
11. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
12. WHO handbook for reporting results of cancer treatment (1979), World Health Organization Offset Publication No. 48, Geneva (Switzerland)
13. Le Scodan R., Mornex F., Partensky C., et al. [Study of chemosensibility of pancreatic ductal carcinoma in 41 patients included into the FFCD-SFRO 97-04 trial]. [abstract]. Gastroenterol Clin Biol 28 (2004) A91
14. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Kamthan A.G., Morris J.C., Dalton J., et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15 (1997) 2920-2927
16. Safran H., King T.P., Choy H., et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer. A phase I study. J Clin Oncol 15 (1997) 901-907
17. White R.R., Hurwitz H.I., Morse M.A., et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8 (2001) 758-765
18. Snady H., Bruckner H., Cooperman A., et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89 (2000) 314-327
19. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127 (1992) 1335-1339
20. Yeung R.S., Weese J.L., Hoffman J.P., et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 72 (1993) 2124-2133
21. Ishikawa O., Ohigashi H., Imaoka S., et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?. Arch Surg 129 (1994) 1075-1080
22. Pisters P.W., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16 (1998) 3843-3850
23. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas. An Eastern Cooperative Oncology Group Study. J Clin Oncol 16 (1998) 317-323
24. Pisters P.W., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma. Toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20 (2002) 2537-2544
25. Moutardier V., Magnin V., Turrini O., et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 60 (2004) 437-443
26. Mornex F., Girard N., Partensky C., et al. Radiochemotherapy in the management of pancreatic cancer-Part 1. Neoadjuvant treatment. Semin Radiat Oncol 15 (2005) 226-234